Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inspire Medical Systems (INSP) EBITDA Margin (2017 - 2026)

Inspire Medical Systems' EBITDA Margin history spans 10 years, with the latest figure at 0.55% for Q1 2026.

  • On a quarterly basis, EBITDA Margin fell 188.0% to 0.55% in Q1 2026 year-over-year; TTM through Mar 2026 was 15.47%, a 754.0% increase, with the full-year FY2025 number at 15.94%, up 931.0% from a year prior.
  • EBITDA Margin hit 0.55% in Q1 2026 for Inspire Medical Systems, down from 50.51% in the prior quarter.
  • Over the last five years, EBITDA Margin for INSP hit a ceiling of 50.51% in Q4 2025 and a floor of 24.27% in Q1 2022.
  • Historically, EBITDA Margin has averaged 0.37% across 5 years, with a median of 0.55% in 2026.
  • The widest YoY moves for EBITDA Margin: up 3630bps in 2025, down -645bps in 2025.
  • Tracing INSP's EBITDA Margin over 5 years: stood at 2.49% in 2022, then skyrocketed by 224bps to 8.06% in 2023, then soared by 76bps to 14.21% in 2024, then skyrocketed by 256bps to 50.51% in 2025, then crashed by -101bps to 0.55% in 2026.
  • Business Quant data shows EBITDA Margin for INSP at 0.55% in Q1 2026, 50.51% in Q4 2025, and 4.53% in Q3 2025.